227 related articles for article (PubMed ID: 16412213)
21. Photoinactivated lymphocyte therapy of cutaneous T-cell lymphoma.
Heald P; Knobler R; LaRoche L
Dermatol Clin; 1994 Apr; 12(2):443-9. PubMed ID: 8045055
[TBL] [Abstract][Full Text] [Related]
22. Staging and management of cutaneous T-cell lymphoma.
Scarisbrick JJ
Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
[TBL] [Abstract][Full Text] [Related]
23. Controversies in the management of the cutaneous T cell lymphomas.
Zic JA
Dermatol Ther; 2009; 22(5):407-17. PubMed ID: 19845718
[TBL] [Abstract][Full Text] [Related]
24. Assessing clinical outcomes in cutaneous T-cell lymphoma.
Zackheim HS; Koh HK; Weinstock MA
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1021-9. PubMed ID: 8522482
[TBL] [Abstract][Full Text] [Related]
25. Treatment of cutaneous T-cell lymphoma: an update.
Young JW
J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
27. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
28. The immunopathogenesis of cutaneous T-cell lymphoma.
Rook AH; Heald P
Hematol Oncol Clin North Am; 1995 Oct; 9(5):997-1010. PubMed ID: 8522492
[TBL] [Abstract][Full Text] [Related]
29. Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group.
Sugaya M; Hamada T; Kawai K; Yonekura K; Ohtsuka M; Shimauchi T; Tokura Y; Nozaki K; Izutsu K; Suzuki R; Setoyama M; Nagatani T; Koga H; Tani M; Iwatsuki K
J Dermatol; 2013 Jan; 40(1):2-14. PubMed ID: 22900999
[TBL] [Abstract][Full Text] [Related]
30. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
31. Diffuse large cell non-Hodgkin's lymphoma, CD30+, T-cell phenotype.
Gruson LM; Latkowski JA
Dermatol Online J; 2005 Dec; 11(4):17. PubMed ID: 16403389
[TBL] [Abstract][Full Text] [Related]
32. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat.
Massone C; Lozzi GP; Egberts F; Fink-Puches R; Cota C; Kerl H; Cerroni L
J Cutan Pathol; 2006 Jun; 33(6):418-25. PubMed ID: 16776717
[TBL] [Abstract][Full Text] [Related]
33. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.
Garcia-Herrera A; Colomo L; Camós M; Carreras J; Balague O; Martinez A; Lopéz-Guillermo A; Estrach T; Campo E
J Clin Oncol; 2008 Jul; 26(20):3364-71. PubMed ID: 18541895
[TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
[TBL] [Abstract][Full Text] [Related]
35. Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role.
Ponti R; Bergallo M; Costa C; Quaglino P; Fierro MT; Comessatti A; Stroppiana E; Sidoti F; Merlino C; Novelli M; Alotto D; Cavallo R; Bernengo MG
Br J Dermatol; 2008 Nov; 159(5):1131-7. PubMed ID: 18782321
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification.
Kong YY; Dai B; Kong JC; Zhou XY; Lu HF; Shen L; Du X; Shi DR
Am J Surg Pathol; 2008 Oct; 32(10):1495-502. PubMed ID: 18708940
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous T-cell lymphoma: overview and nursing perspectives.
McCann SA
Nurs Clin North Am; 2007 Sep; 42(3):421-55, vi-vii. PubMed ID: 17825663
[TBL] [Abstract][Full Text] [Related]
39. Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas.
Urosevic M
Curr Opin Investig Drugs; 2007 Jun; 8(6):493-8. PubMed ID: 17621880
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous lymphomas: what can we learn from location?
Grange F; Antonicelli F
Arch Dermatol; 2009 Jun; 145(6):710-2. PubMed ID: 19528430
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
